2-(3-formylphenoxy)ethyl 1-methylcyclopropane carboxylate | 1356489-42-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(3-formylphenoxy)ethyl 1-methylcyclopropane carboxylate
• 英文别名: 2-(3-Formylphenoxy)ethyl-1-methylcyclopropane carboxylate；2-(3-formylphenoxy)ethyl 1-methylcyclopropane-1-carboxylate
• CAS: 1356489-42-3
• 化学式: C₁₄H₁₆O₄
• 分子量: 248.279
• InChiKey: PJWVFWJRMSAETQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-N-(pyrrolidin-3-yl)isoquinolin-5-amine 、 2-(3-formylphenoxy)ethyl 1-methylcyclopropane carboxylate 在 三乙酰氧基硼氢化钠 、 水 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 2-(3-(((R)-3-(isoquinolin-5-ylamino)pyrrolidin-1-yl)methyl)phenoxy)ethyl 1-methylcyclopropanecarboxylate
  参考文献：
  名称：

  [EN] METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS
  [FR] MÉTHODE DE TRAITEMENT DE MALADIES OPHTALMIQUES À L'AIDE DE COMPOSÉS D'INHIBITEURS DE KINASE SOUS FORME DE PROMÉDICAMENTS

  摘要：

  这项发明涉及罗激酶（ROCK）抑制剂的前药。这些前药通常是母化合物的酯或酰胺衍生物。这些前药通常是ROCK的弱抑制剂，但它们的母化合物具有良好的活性。将这些前药滴入眼中后，其酯或酰胺基团会迅速水解成醇、胺或酸，前药会转化为活性的基本化合物。ROCK抑制剂的前药提供了几个优点，如将更高浓度的活性物质传递到目标部位，减少眼部不适。该发明还涉及通过向需要的患者眼部给予公式（I）的ROCK前药化合物的有效量来治疗青光眼、过敏性结膜炎、黄斑水肿、黄斑变性和睑缘炎等眼科疾病的方法。

  公开号：

  WO2012015760A1

文献信息

• METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS
  申请人：Inspire Pharmaceuticals, Inc.

  公开号：US20130131059A1

  公开（公告）日：2013-05-23

  This invention is directed to prodrugs of rho kinase (ROCK) inhibitors. These prodrugs are in general the ester or the amide derivatives of the parent compounds. These prodrugs are often weak inhibitors of ROCK, but their parent compounds have good activities. Upon instillation into the eyes, the ester or the amide group of these prodrugs is rapidly hydrolyzed into alcohol, amine, or acid, and the prodrugs are converted into the active base compounds. The prodrugs of ROCK inhibitors provide several advantages such as delivery of higher concentrations of the active species into the target site and reduction of ocular discomfort. The invention is also directed to a method of treating ophthalmic diseases such as glaucoma, allergic conjunctivitis, macular edema, macular degeneration, and blepharitis, by administering an effective amount of a ROCK prodrug compound of Formula I to the eyes of the patient in need of.

  本发明涉及rho激酶（ROCK）抑制剂的前药。这些前药通常是母化合物的酯或酰胺衍生物。这些前药通常是ROCK的弱抑制剂，但它们的母化合物具有良好的活性。将这些前药滴入眼睛后，其酯或酰胺基团会迅速水解为醇，胺或酸，并将前药转化为活性基础化合物。ROCK抑制剂的前药提供了几个优点，如将更高浓度的活性物种输送到目标部位以及减少眼部不适。本发明还涉及通过向需要的患者眼睛中投与公式I的ROCK前药化合物的有效量来治疗眼科疾病，如青光眼，过敏性结膜炎，黄斑水肿，黄斑变性和睑缘炎的方法。
• [EN] METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS<br/>[FR] MÉTHODE DE TRAITEMENT DE MALADIES OPHTALMIQUES À L'AIDE DE COMPOSÉS D'INHIBITEURS DE KINASE SOUS FORME DE PROMÉDICAMENTS
  申请人：INSPIRE PHARMACEUTICALS INC

  公开号：WO2012015760A1

  公开（公告）日：2012-02-02

  This invention is directed to prodrugs of rho kinase (ROCK) inhibitors. These prodrugs are in general the ester or the amide derivatives of the parent compounds. These prodrugs are often weak inhibitors of ROCK, but their parent compounds have good activities. Upon instillation into the eyes, the ester or the amide group of these prodrugs is rapidly hydrolyzed into alcohol, amine, or acid, and the prodrugs are converted into the active base compounds. The prodrugs of ROCK inhibitors provide several advantages such as delivery of higher concentrations of the active species into the target site and reduction of ocular discomfort. The invention is also directed to a method of treating ophthalmic diseases such as glaucoma, allergic conjunctivitis, macular edema, macular degeneration, and blepharitis, by administering an effective amount of a ROCK prodrug compound of Formula (I) to the eyes of the patient in need of.

  这项发明涉及罗激酶（ROCK）抑制剂的前药。这些前药通常是母化合物的酯或酰胺衍生物。这些前药通常是ROCK的弱抑制剂，但它们的母化合物具有良好的活性。将这些前药滴入眼中后，其酯或酰胺基团会迅速水解成醇、胺或酸，前药会转化为活性的基本化合物。ROCK抑制剂的前药提供了几个优点，如将更高浓度的活性物质传递到目标部位，减少眼部不适。该发明还涉及通过向需要的患者眼部给予公式（I）的ROCK前药化合物的有效量来治疗青光眼、过敏性结膜炎、黄斑水肿、黄斑变性和睑缘炎等眼科疾病的方法。